Investor Overview Press Releases May 8, 2019 Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments May 1, 2019 Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019 April 25, 2019 Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis View all » Events May 8, 20195:00 PM EDT Q1 2019 Aclaris Therapeutics Inc. Earnings Conference Call Mar 18, 20198:00 AM EDT Q4 2018 Aclaris Therapeutics Inc. Earnings Conference Call Feb 27, 2019 Aclaris Therapeutics, Inc. at 8th Annual Leerink Partners Global Healthcare Conference View all » Feature presentation Aclaris Therapeutics Company Overview
May 8, 2019 Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments
April 25, 2019 Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis
